Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …

Abstract The Asian Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL Consensus Statements and Management …

Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were
the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained …

BACKGROUND & AIMS: Recent studies have shown that 12 weeks of treatment with
telaprevir, administered every 8 hours (q8h), combined with pegylated interferon …

The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a
standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and …

OBJECTIVE: To assess the effectiveness of treatment for hepatitis C virus (HCV) infection in
low-and middle-income countries and identify factors associated with successful outcomes …

Background. A systematic review and meta-analysis were conducted to examine the efficacy
and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) …

BACKGROUND & AIMS: Patients with recurrent hepatitis C virus infection treated with
pegylated interferon (PEG) after liver transplantation can develop severe immune-mediated …

Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a
standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination …

By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of
interferon (IFN)‐based antiviral therapy, crucial parameters of the in vivo viral kinetics have …